VENUS REMEDIES Financial Statement Analysis
|
||
The Revenues of VENUS REMEDIES have increased by 9.50% YoY .
The Earnings Per Share (EPS) of VENUS REMEDIES has decreased by -34.79 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
VENUS REMEDIES Last 5 Annual Financial Results
[BOM: 526953|NSE : VENUSREM]
Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
---|---|---|---|---|---|
Revenues | ₹600 Cr | ₹548 Cr | ₹339 Cr | ₹322 Cr | ₹372 Cr |
Expenses | ₹538 Cr | ₹494 Cr | ₹299 Cr | ₹289 Cr | ₹333 Cr |
Operating Profit (Excl OI) | ₹62 Cr | ₹54 Cr | ₹41 Cr | ₹33 Cr | ₹39 Cr |
Other Income | ₹8.31 Cr | ₹20 Cr | ₹5.31 Cr | ₹6.09 Cr | ₹2.39 Cr |
Interest | ₹0.48 Cr | ₹13 Cr | ₹13 Cr | ₹25 Cr | ₹36 Cr |
Depreciation | ₹34 Cr | ₹35 Cr | ₹32 Cr | ₹34 Cr | ₹34 Cr |
Profit Before Tax | ₹36 Cr | ₹49 Cr | ₹-8.04 Cr | ₹-30 Cr | ₹-28 Cr |
Profit After Tax | ₹41 Cr | ₹62 Cr | ₹-10.00 Cr | ₹-29 Cr | ₹-31 Cr |
Consolidated Net Profit | ₹41 Cr | ₹62 Cr | ₹-10.00 Cr | ₹-29 Cr | ₹-31 Cr |
Earnings Per Share (Rs) | ₹19.87 | ₹30.47 | ₹50.04 | ₹-8.10 | ₹-23.15 |
PAT Margin (%) | 4.78 | 6.79 | 11.27 | -2.95 | -8.88 |
ROE(%) | 5.90 | 9.85 | 17.40 | -3.05 | -8.23 |
ROCE(%) | 7.75 | 7.89 | 12.37 | 0.90 | -0.67 |
Total Debt/Equity(x) | 0.09 | 0.10 | 0.13 | 0.68 | 0.90 |
Key Financials |
||
Market Cap | : | ₹ 448.5 Cr |
Revenue (TTM) | : | ₹ 561.9 Cr |
Net Profit(TTM) | : | ₹ 29.0 Cr |
EPS (TTM) | : | ₹ 21.7 |
P/E (TTM) | : | 15.4 |
Industry Peers & Returns | 1W | 1M | 1Y |
VENUS REMEDIES | -4% | -12.1% | 89.2% |
SUN PHARMACEUTICAL INDUSTRIES | 3% | 2.3% | 68.2% |
CIPLA | 2.5% | 0.4% | 71.7% |
DR REDDYS LABORATORIES | -0.2% | -4.9% | 40.3% |
ZYDUS LIFESCIENCES | 5% | 10.4% | 109.1% |
DIVIS LABORATORIES | -1.6% | -7% | 23.8% |
MANKIND PHARMA | NA | NA | NA |
TORRENT PHARMACEUTICALS | 2.9% | -2.2% | 69% |
LUPIN | 2.8% | 0% | 147.8% |
VENUS REMEDIES Revenues
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 9.50 % |
5 Yr CAGR | 12.67 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2023 | ₹600 Cr | 9.50 | |
Mar2022 | ₹548 Cr | 61.53 | |
Mar2021 | ₹339 Cr | 5.42 | |
Mar2020 | ₹322 Cr | -13.57 | |
Mar2019 | ₹372 Cr | - |
VENUS REMEDIES Operating Profit
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | 15.50 % |
5 Yr CAGR | 12.00 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2023 | ₹62 Cr | 15.50 | |
Mar2022 | ₹54 Cr | 31.75 | |
Mar2021 | ₹41 Cr | 25.50 | |
Mar2020 | ₹33 Cr | -17.60 | |
Mar2019 | ₹39 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | 5.50 % |
5 Yr CAGR | -0.59 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2023 | 10.35% | 5.50 | |
Mar2022 | 9.81% | -18.45 | |
Mar2021 | 12.03% | 19.11 | |
Mar2020 | 10.1% | -4.72 | |
Mar2019 | 10.6% | - |
VENUS REMEDIES Profit After Tax
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | -34.07 % |
5 Yr CAGR | Positive |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2023 | ₹41 Cr | -34.07 | |
Mar2022 | ₹62 Cr | Positive | |
Mar2021 | ₹-10.00 Cr | Negative | |
Mar2020 | ₹-29 Cr | Negative | |
Mar2019 | ₹-31 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -29.60 % |
5 Yr CAGR | Positive |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2023 | 4.78 % | -29.60 | |
Mar2022 | 6.79 % | -39.75 | |
Mar2021 | 11.27 % | Positive | |
Mar2020 | -2.95 % | Negative | |
Mar2019 | -8.88 % | - |
VENUS REMEDIES Earnings Per Share (EPS)
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | -34.79 % |
5 Yr CAGR | Positive |
Years | EPS | % Change | |
---|---|---|---|
Mar2023 | ₹20 | -34.79 | |
Mar2022 | ₹30 | -39.11 | |
Mar2021 | ₹50 | Positive | |
Mar2020 | ₹-8.10 | Negative | |
Mar2019 | ₹-23 | - |
VENUS REMEDIES Return on Capital Employed (ROCE)
[BOM: 526953|NSE : VENUSREM]
Y-o-Y | -1.77 % |
5 Yr CAGR | Positive |
Years | ROCE | % Change | |
---|---|---|---|
Mar2023 | 7.75% | -1.77 | |
Mar2022 | 7.89% | -36.22 | |
Mar2021 | 12.37% | 1,274.44 | |
Mar2020 | 0.9% | Positive | |
Mar2019 | -0.67% | - |
VENUS REMEDIES Share Price vs Sensex
Current Share Price | : | ₹334.7 |
Current MarketCap | : | ₹ 448.5 Cr |
Updated EOD on | : | Apr 18,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
VENUS REMEDIES | -4% |
-12.1% |
89.2% |
SENSEX | -2.9% |
-0.4% |
20% |
VENUS REMEDIES related INDICES
You may also like the below Video Courses
FAQ about VENUS REMEDIES Financials
How the annual revenues of VENUS REMEDIES have changed ?
The Revenues of VENUS REMEDIES have increased by 9.50% YoY .
How the Earnings per Share (EPS) of VENUS REMEDIES have changed?
The Earnings Per Share (EPS) of VENUS REMEDIES has decreased by -34.79 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs